Short answer
LB PHARMACEUTICALS INC (LBRX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$59M
- −330.1% YoY · −14.5% QoQ
- EPS (diluted)
- −$1.83
- +70.8% YoY · −4.6% QoQ
Source: XBRL data from the LB PHARMACEUTICALS INC (LBRX) Q3 2026 10-Q on SEC EDGAR. USD.
LB PHARMACEUTICALS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- Net loss $59.1M vs $3.6M YoY, operating loss $62.5M vs $5.2M
- R&D highest spending area: $51.5M, up from $2.4M, driven by schizophrenia trials
- Cash, equivalents and short-term investments $403.8M at September 30, 2026
- Operating cash use $125.2M, financing provided $234.7M, investments used $144.6M
- Outlook: continued losses, cash runway beyond Q2 2029, clinical development and expenses rising significantly
Risk Factors
- Newly added AI risk: EU AI Act exposure, with noncompliance fines up to €35 million or 7% of worldwide annual turnover
- Most material update, financial reporting: Unremediated internal-control weaknesses, with remediation targeted by December 31, 2026
- Regulatory risk: FDA may reject Phase 2 acute-schizophrenia data as one of two pivotal NDA trials
- Operational risk: Clinical-trial enrollment delays or withdrawals could compromise data quality and extend development timelines
- Liquidity risk: $403.8 million in cash, equivalents and short-term investments funds operations for at least 12 months, but additional capital remains required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LB PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.